3Altundag K.Neoadjuvant chemotherapy with cyclophamide,mitoxantrone,and 5-fluorouracil in locally advanced breast cancer[J].Onkologie,2005,28(2):81-85. 被引量：1
4MacGrogan G,Mauriac L,Durand M,et al.Primary chemotherapy in breast invasive carcinoma:predictive value of the immunohistochemical detection of hormonal receptors,p53,c-erbB-2,MiB 1,pS2 and GST pi[J].Br J Cancer,1996,74(9):1458-1465. 被引量：1
5Rozan S,Vincent-Salomon A,Zafrani B,et al.No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer[J].Int J Cancer,1998,79(1):27-33. 被引量：1
6Berry DA,Cirrincione C,Henderson IC,et al.Estrogen-receptor status and outcomes of moderm chemotherapy for patients with node-positive breast cancer[J].JAMA,2006,295(14):1658-1667. 被引量：1
7Lamon DJ,Clark GM,Wong SG,et al.Human breast cancer correlationof relapse and survival with amplification of the HER-2/neu oncogene[J].Science,1987,235(4785):177-182. 被引量：1
8Steger GG,Wenzel C,Schmidinger M,et al.Predictive factors for a complete pathological response in primary breast cancer treated neoadjuvantly with epirubicin/taxane+G-CSF regimen[J].Proc Am Soc Clin Oncol,2001,20:39a(abstract 154). 被引量：1
3Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulat- ing evidence of efficacy, synergy and safety[J].Cfit Rev Oncol He-matol, 2008, 66(1):31-41. 被引量：1
4Many M, Cognetti F, Maraninchi D, et al. Randomized phase II tri al of the efficacy and safety of trastuzumab combined with docetax el in patients with human epidermal growth factor receptor 2-posl five metastatic breast cancer administered as first-line treatment the M77001 study group[J].J Clin Oncol, 2005, 23(19):4265--4274. 被引量：1
5Mauri D, Pavlidis N, IoannidisJP. Neoadjuvant versus adjuvant sys- temic treatment in breast cancer: a meta-analysis[J], j Nad Cancer Inst, 2005, 97(3):188-194. 被引量：1
6BaselgaJ, Norton L, AlbanellJ, et al. Recombinant humanized an ti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing hu- man breast cancer xenografts[J]. Cancer Res, 1998, 58(13): 2825-2831. 被引量：1
7Veldhoen R A,Banman S L,Hemmerling D R,et al.The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis[J].Oncogene,2013;32(6):736-746. 被引量：1
8Chen W C,Kim J,Kim E,et al.A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer[J].International Journal of Radiation Ontology Biology Physics,2012;82(1):14-20. 被引量：1
9Rapoport B L,Demetriou G S,Moodley S D,et al.When and how do I use neoadjuvant chemotherapy for breast cancer[J].Curr Treat Options Oncol,2014,15(1):86. 被引量：1
10Redden M H,Fuhrman G M.Neoadjuvant chemotherapy in the treatment of breast cancer[J].Sutg Clin North Am,2013,93(2):493. 被引量：1
